Shares of Anacor Pharmaceuticals (NASDAQ: ANAC) jumped 26% one day, and 30% the next, with an even bigger catalyst on the horizon. What is driving these explosive share price surges? In the video below, Fool analyst David Williamson discusses one phase 2 trial that has the markets excited, and tells us why the results from its upcoming phase 3 trial for this candidate pipeline drug could be even bigger.
